Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imiquimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 15/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.97 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.97 |
| ▸ | HRH2 | P25021 | 1/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imiquimod SCHEMBL26136 | 0.99 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29357252 | 0.99 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL570774 | 0.99 | TLR7 (1.00) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL29029396 | 0.97 | TLR7 (0.93) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL17962753 | 0.97 | TLR7 (0.97) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5262205 | 0.93 | TLR7 (0.88) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3191041 | 0.92 | TLR7 (0.86) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL3415170 | 0.91 | TLR7 (0.84) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL5260618 | 0.90 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB | |
| Imiquimod SCHEMBL9602834 | 0.90 | TLR7 (0.82) | TLR7PDE4DADORA2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112438944-B | Temperature-sensitive gel pharmaceutical composition for treating tumors | 苏州百迈生物医药有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-116212016-A | Immune adjuvant-loaded phycocyanin nano-system and preparation method and application thereof | 江苏大学 | 2023-06-06 | — | — | CN | claimed |
| WO-2021042778-A1 | TEMPERATURE-SENSITIVE GEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUMORS | 苏州百迈生物医药有限公司 | 2021-03-11 | — | — | WO | claimed |
| CN-112438944-A | Temperature-sensitive gel pharmaceutical composition for treating tumors | 苏州百迈生物医药有限公司 | 2021-03-05 | — | — | CN | claimed |
| CN-111375065-A | Biopolymer pharmaceutical composition for tumor treatment | 苏州百迈生物医药有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-111375062-A | Biopolymer pharmaceutical composition for in-situ gel-forming chemotherapy and immune combination therapy | 苏州百迈生物医药有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-110693850-A | Preparation method of imiquimod chitosan nanoparticles | 湖北科益药业股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| CN-104402878-A | Preparation method of imiquimod | TIANFANG PHARMACEUTICAL CO LTD | 2015-03-11 | — | — | CN | claimed |
| EP-0394026-B1 | Formulation containing an imidazo[4,5-c]quinolin derivative | RIKER LABORATORIES, INC. (US) | 1993-09-29 | — | — | EP | claimed |
| WO-2025104289-A1 | ANTINEOPLASTIC COMBINATIONS | MEDINCELL S.A. (FR) | 2025-05-22 | — | — | WO | disclosed |
| CN-113730570-B | Chemotherapy immune combination medicine and application thereof | 苏州百迈生物医药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240398841-A1 | BLADDER PERFUSION PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | INNOBM PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118845625-A | Imiquimod hydrogel and application thereof in preparation of HPV immunotherapy medicaments | 浙江大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-114681612-B | Bladder perfusion medicine and preparation method and application thereof | 苏州百迈生物医药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-0310950-B1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0394026-A1 | Formulation containing an imidazo[4,5-c]quinolin derivative | RIKER LABORATORIES, INC. (US) | 1990-10-24 | — | — | EP | disclosed |
| EP-0145340-B1 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0310950-A1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | disclosed |
| EP-0145340-A2 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398841-A1 | BLADDER PERFUSION PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BAD, BPHL, HASPIN | TLR7 728/4885PDE4D 1014/4885ADORA2A 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.